Investigating metabolic and lipid profiles in diabetic eye disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to recruit individuals with diabetes and varying stages of diabetic eye disease to analyze blood and urine samples for metabolic and lipidomic profiles. The research will explore the relationship between these profiles and the damage to the retina caused by diabetic retinopathy and diabetic macular edema. Additionally, the study will examine gut bacteria that may influence eye disease through circulating chemicals. Participants will have their medical records reviewed to support the findings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of type 2 diabetes mellitus
* Male or female aged 18 - 80 inclusive

Exclusion Criteria:

* Participant unable or unwilling to consent to inclusion in the study
* Prior treatment with intravitreal therapies for DMO
* Potential participant with a known infective disease that may put the study team at risk (eg. TB, HIV, hepatitis)
* Age 17 yo or less or 81 yo or older
* Known underlying genetic condition affecting lipid metabolism

Where it's running

• Prince Philip Hospital
  Llanelli, Wales, United Kingdom Recruiting

Study contacts

• Principal investigator: Francis WB Sanders, MB BChir PhD FRCOphth — Hywel Dda University Health Board
• Study coordinator: Francis WB Sanders, MB BChir PhD FRCOphth
• Email: francis.sanders@wales.nhs.uk
• Phone: +447717171199

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early imaging changes with faricimab versus biosimilar ranibizumab for diabetic retinal disease

  This trial will see if faricimab or a biosimilar ranibizumab causes different early OCT and OCTA imaging changes in adults with diabetic retinopathy or diabetic macular edema who need anti-VEGF injections.

  Recruiting Osijek University Hospital · Osijek · NCT07520045

• New-generation diabetes medicines and the onset of diabetic retinopathy

  This study will test whether newer diabetes medicines (SGLT2 and DPP‑4 inhibitors) can delay diabetic retinopathy in people with type 2 diabetes who've had the disease for more than five years and have been on diabetes medications for 2–3 years.

  Recruiting Alexandria University · Alexandria · NCT07351786

• Oral N-Acetylcysteine for Diabetic Macular Edema

  This study tests whether taking N-acetylcysteine by mouth can help people with center-involving diabetic macular edema who don’t yet need anti-VEGF therapy.

  Recruiting Phase 2 Tanta University · Damietta · NCT07917338

• 4D-150 gene therapy injected into the eye for adults with diabetic macular edema

  This study tests whether a one-time intravitreal injection of 4D-150 can help adults with diabetic macular edema compare to aflibercept.

  Recruiting at 23 sites Phase 3 4D Molecular Therapeutics · Scottsdale, Arizona and 93 other locations · NCT07867080

• Automated AI system to detect diabetic retinopathy in adults with diabetes

  A AI-based software device is being tested to automatically detect diabetic retinopathy from retinal images in adults with diabetes.

  Recruiting Digital Diagnostics, Inc. · Jacksonville, Florida · NCT07844317

• Corticosteroid for Diabetic Macular Edema (DME) in Adults with Diabetic Retinopathy

  This trial tests whether intravitreal corticosteroid injections can influence inflammatory biomarkers and improve DME in adults with type 2 diabetes.

  Recruiting Phase 4 Vanderbilt University Medical Center · Nashville, Tennessee · NCT07843849

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.